Tempus HRD Flashcards
What is HRR?
Homologous Recombination Repair
What is it?
it’s a mechanism in our bodies that prevents cancer from happening.
Proteins that are part of the HRR pathway recognize that a double-stranded DNA break has occurred and send out a signal. T or F?
True
What are the steps here?
- ) Other proteins in the HRR pathway assemble and create a repair complex
2) The repair complex “recruits” the chromosome’s homolog and brings it over to serve as a template. - ) Using that template, the repair complex is able to rebuild the broken DNA strands of the original chromosome.
HRD occurs when the HRR is not functioning properly, T or F?
True
T or F, HRR pathway is highly complex and multiple genes and proteins are involved ?
True
What genes are included in this?
BRCA1 and BRCA2
Two-hit hypothesis
First hit and second
First hit:
Germline or Somatic mutation in the HR gene
Second hit:
Somatic mutation or other mechanisms inactivates the second copy, leads to “loss of heterozygosity” for that gene.
HRD is observed in multiple cancer types. T or F?
True
T or F, approx 50% of ovarian cancer is HR- deficient?
True
HRD is also seen in what cancer types?
- Breast
- Prostate
- Pancreas
HRD is a relatively common feature of cancer development, T or F?
True
HRD occurs when ____ are not recognized and repaired by proteins in the HRR pathway
Double-stranded breaks
T or F, loss of function of either BRCA1 or BRCA2 is a possible mechanism which leads to HRD?
True
In which of these cancers is HRD NOT frequently observed?
Lung
Can A “PARP” protein be the one to go in and repair damage?
Yes, this inhibitor can cause the cancer to die.
PARP inhibitor therapy is somewhat limited by the FDA, T or F?
True. There has to be a gBRCAm, HRR gene mutation or BRCA mut.
Tempus CANNOT claim any association to therapies including:
1) Eligibility for PARPi therapy
2) Response to PARPi therapy
3) platinum chemotherapy eligibility
4) platinum chemo treatment response
Which statement about PARP inhibitors is “false”?
They are most effective in patients who do not have HRD
The FDA has approved PARP inhibitors for:
- Breast cancers w/ germline BRCA mutations
- Prostate cancer w/ HRR mutations
- Pancreatic cancer w/ germline BRCA mutations
- Ovarian cancers regardless of HRR mutation status
T or F, Tempus cannot claim any association with the Tempus HRD status with eligibility for or response to PARP inhibitors-
True
What is the Tempus HRD test designed for?
to identify patients whose tumor has an HRD molecular phenotype.
